US · Healthcare · Medical Devices
EPS came in at 0.70 against a street estimate of 0.61 — a beat of 14.8%.
Analysts rate DexCom Inc a strong buy (24 buy, 3 hold, 0 sell out of 27) with an average price target of $92.80.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.33% |
| Vanguard Capital Management, LLC | 6.63% |
| Vanguard Portfolio Management, LLC | 5.09% |
| State Street Corp | 4.75% |
| Baillie Gifford & Co Limited. | 4.13% |
| Amvescap Plc. | 3.62% |
| AllianceBernstein L.P. | 3.42% |
| Geode Capital Management, LLC | 3.27% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-30 |
| Results announced · Q3 2026 | 2026-07-30 |
| Shareholder vote results · Q2 2026 | 2026-05-28 |
| Reg FD disclosure · Q2 2026 | 2026-05-15 |
| Quarterly report · Q1 2026 | 2026-04-30 |
| Results announced · Q2 2026 | 2026-04-30 |
| Proxy statement · Q2 2026 | 2026-04-15 |
| Annual report FY2025 | 2026-02-12 |
Readable in the app.
| Announcement | Date |
|---|---|
| Board authorizes $1.0 billion share repurchase program through June 2027 Dexcom announced on May 14, 2026, that its Board of Directors approved a new $1.0 billion share repurchase program, effective through June 30, 2027. The company terminated its previous repur | 2026-05-15 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for DexCom Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.